There is no single test for blood cancer. Diagnosis typically starts with a simple blood draw and, if results are abnormal, moves through increasingly specialized tests that can take several weeks to complete. Unlike cancers of the breast, colon, or lung, blood cancers have no routine screening test recommended for people without symptoms. Most cases are caught when a doctor orders bloodwork for another reason or investigates symptoms like unexplained fatigue, frequent infections, easy bruising, or swollen lymph nodes.
The diagnostic process follows a predictable sequence: blood tests first, then bone marrow or tissue sampling, then genetic and molecular analysis to pin down the exact type. Here’s what each step involves and what to expect.
The Complete Blood Count Comes First
Nearly every blood cancer workup begins with a complete blood count, or CBC. This routine test measures three key cell types your bone marrow produces: red blood cells, white blood cells, and platelets. Normal adult white blood cell counts fall between 3.4 and 9.6 billion cells per liter. Hemoglobin, the oxygen-carrying protein in red blood cells, typically ranges from 13.2 to 16.6 grams per deciliter in men and 11.6 to 15 in women. Platelet counts normally sit between 135 and 371 billion per liter, depending on sex.
Results outside these ranges don’t automatically mean cancer. Infections, nutritional deficiencies, and many other conditions shift blood counts. But certain patterns raise suspicion: a white blood cell count that’s very high or very low, a drop in platelets without an obvious cause, or anemia that doesn’t respond to iron supplements. When a CBC flags something unusual, the next step is usually a peripheral blood smear, where a technician examines a drop of your blood under a microscope to look for cells that are abnormal in shape, size, or maturity. Immature white blood cells circulating in the bloodstream, called blasts, are a strong signal that something is wrong in the bone marrow.
Bone Marrow Biopsy: The Key Confirmation Test
If blood tests suggest a problem, a bone marrow biopsy is the most important step for confirming a diagnosis. This procedure collects two types of samples: an aspiration, which draws out the liquid portion of the marrow, and a core biopsy, which removes a small cylinder of the solid tissue. Both are usually taken from the back ridge of the hipbone under local anesthesia. In some cases the front of the hip is used instead, and rarely, aspiration alone is taken from the breastbone.
The procedure itself takes about 15 to 30 minutes. You’ll feel pressure and a brief, sharp pulling sensation during the aspiration. A pathologist then examines both samples to assess the number, type, and maturity of cells being produced. In leukemia, the marrow is often packed with abnormal cells that crowd out healthy ones. In myeloma, the pathologist looks for an excess of plasma cells. These findings, combined with your blood results, form the backbone of a diagnosis.
Flow Cytometry and Cell Typing
Once abnormal cells are identified, doctors need to know exactly what kind they are. Flow cytometry does this by tagging proteins on the surface of cells with fluorescent dyes, then passing thousands of cells per second through a laser beam. Each cell type carries a distinct pattern of surface proteins. A healthy cell’s pattern matches what you’d expect for its type and stage of development. Cancer cells display different patterns, and these differences tell doctors whether they’re dealing with a B-cell lymphoma versus a T-cell lymphoma, or acute lymphoblastic leukemia versus acute myeloid leukemia.
This distinction matters enormously for treatment. Two blood cancers that look similar under a microscope can behave very differently and respond to completely different therapies. Flow cytometry can be run on blood samples, bone marrow, or fluid drained from swollen lymph nodes, and results typically come back within a few days.
Genetic and Chromosomal Testing
Modern blood cancer diagnosis goes beyond identifying the cell type. Genetic testing examines the DNA inside cancer cells for specific chromosomal changes and gene mutations that influence how the disease will behave and which treatments will work best.
The most well-known example is the Philadelphia chromosome, found in most cases of chronic myeloid leukemia (CML). This abnormality occurs when pieces of chromosomes 9 and 22 swap places, creating a fused gene that drives uncontrolled cell growth. Detecting it is essential because targeted therapies exist specifically for this mutation. About 5 to 10 percent of CML patients have variant forms of this translocation that standard chromosome analysis can miss, so a technique called FISH (fluorescent in situ hybridization) is used to catch them. FISH uses fluorescent probes that bind directly to the genes involved, lighting up the abnormality even when it’s hidden.
Beyond CML, dozens of other chromosomal and genetic changes help classify blood cancers. Some mutations signal a more aggressive disease that needs intensive treatment. Others indicate a slower-growing cancer that can be monitored. These molecular results can take one to three weeks to come back because the testing is complex, so there’s often a waiting period between the initial biopsy and the final, fully classified diagnosis.
Imaging for Lymphoma and Staging
For lymphomas and some other blood cancers, imaging plays a central role. PET-CT scans combine two technologies: a PET scan that detects metabolically active cells (cancer cells burn through sugar faster than normal tissue) and a CT scan that provides detailed anatomical images. International guidelines now recommend PET-CT over standard CT for staging lymphomas because it’s more accurate at identifying where disease has spread.
PET-CT is particularly good at finding cancer in unexpected locations. In studies of Hodgkin lymphoma, PET-CT frequently upstaged patients by detecting disease in bone marrow or lymph nodes below the diaphragm that CT alone would have missed. It also prevents overtreatment by downstaging patients whose enlarged lymph nodes or spleens turn out not to contain active cancer. Staging determines the extent of disease and directly shapes treatment decisions, so getting it right matters.
For leukemias, imaging is less central because the disease is already widespread in the blood and marrow. However, CT or ultrasound may be used to check for enlarged organs. In acute leukemias, a lumbar puncture (spinal tap) is sometimes performed to check whether cancer cells have reached the fluid surrounding the brain and spinal cord.
Lymph Node Biopsy
When lymphoma is suspected, often because of persistently swollen lymph nodes, a biopsy of the node itself may be needed. This can be done as an excisional biopsy, which removes an entire lymph node for examination, or as a core needle biopsy, which extracts a small tissue sample. The excisional approach gives the pathologist more tissue to work with and is generally preferred when lymphoma is the primary concern, since the architecture of the node itself helps distinguish between lymphoma subtypes.
What the Timeline Looks Like
From the first abnormal blood test to a complete diagnosis, the process typically spans two to four weeks. A CBC and blood smear can return results within a day or two. A bone marrow biopsy is usually scheduled within a week of abnormal findings, with preliminary results available in a few days and final pathology taking longer. Flow cytometry adds another few days. The genetic and chromosomal tests are the slowest piece, often requiring one to three weeks.
This waiting period can feel agonizing, but the thoroughness has a purpose. Blood cancers encompass dozens of distinct diseases, and the specific subtype determines which treatment gives you the best outcome. Rushing to a general diagnosis of “leukemia” or “lymphoma” without the molecular details can mean starting the wrong therapy. Your medical team will typically wait for the full picture before recommending a treatment plan.
No Routine Screening Exists Yet
Unlike breast, colon, cervical, lung, and prostate cancers, there are no recommended screening tests for blood cancers in people without symptoms. The American Cancer Society’s screening guidelines do not include any blood cancer tests for average-risk adults. This means most blood cancers are found either incidentally through routine bloodwork or after symptoms prompt a medical visit.
Liquid biopsy technology, which detects fragments of tumor DNA circulating in the bloodstream, is advancing rapidly. The FDA approved its first liquid biopsy screening test in 2024, for colorectal cancer. Multi-cancer early detection tests like Galleri are being evaluated in large-scale clinical trials sponsored by the National Cancer Institute, and these aim to detect many cancer types from a single blood draw. But for now, these tools are strongest for monitoring known cancers and guiding treatment decisions rather than catching new blood cancers in otherwise healthy people.